Celldex Therapeutics, Inc. - 8-K Filing
Celldex Therapeutics stockholders approved an amendment to increase the share reserve of its 2021 Omnibus Equity Incentive Plan by 3,400,000 shares, bringing the total available for issuance under the plan to 12,900,000. The vote occurred at the June 25, 2026 Annual Meeting of Stockholders with 58,844,414 votes in favor and 1,654,297 against (plus 185,005 abstentions). Other proposals included electing nine directors with all nominees receiving over 59 million 'for' votes each, ratifying PricewaterhouseCoopers as auditors with strong support, and approving executive compensation on an advisory... (Items: 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi, 5.07 Submission of Matters to a Vote of Security Holders, 9.01 Financial Statements and Exhibits)
Tickers: $CLDX